Medical Prevention of Breast Cancer

被引：12
作者：
Stubert, Johannes [1 ]
Dieterich, Max [1 ]
Gerber, Bernd [1 ]
机构：
[1] Univ Rostock, Dept Obstet & Gynecol, D-18059 Rostock, Germany
来源：
BREAST CARE | 2014年 / 9卷 / 06期
关键词：
Breast cancer; Prevention; Tamoxifen; SERMs; Aromatase inhibitors; SURGICAL ADJUVANT BREAST; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; BOWEL PROJECT; CLINICAL-TRIALS; FAMILY-HISTORY; FOLLOW-UP; RISK;
D O I：
10.1159/000369573
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Breast cancer is the most common cancer of women in Western Europe and North America. Effective strategies of medical prevention could reduce the burden of breast cancer mortality. The best evidence for a risk reduction exists for hormonal agents such as tamoxifen and raloxifene (22-72%) or aromatase inhibitors (50-65%). However, the severity of side effects and the lack of evidence for an improved survival compromise the risk/benefit balance. In this review the results of chemoprevention studies, including new treatment approaches, are summarized with critical discussion of their use in clinical practice.
引用
收藏
页码：391 / 396
页数：6
相关论文
共 63 条
[1]  
[Anonymous], 2013, Krebs in Deutschland 2009/2010
[2]  
9. Ausgabe
[3]   Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study [J].
Bardia, Aditya ;
Olson, Janet E. ;
Vachon, Celine M. ;
Lazovich, DeAnn ;
Vierkant, Robert A. ;
Wang, Alice H. ;
Limburg, Paul J. ;
Anderson, Kristin E. ;
Cerhan, James R. .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (01) :149-155
[4]   Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women [J].
Barrett-Connor, Elizabeth ;
Mosca, Lori ;
Collins, Peter ;
Geiger, Mary Jane ;
Grady, Deborah ;
Kornitzer, Marcel ;
McNabb, Michelle A. ;
Wenger, Nanette K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (02) :125-137
[5]   Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease [J].
Beral, V ;
Bull, D ;
Doll, R ;
Peto, R ;
Reeves, G .
LANCET, 2001, 358 (9291) :1389-1399
[6]   Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial [J].
Bonanni, Bernardo ;
Puntoni, Matteo ;
Cazzaniga, Massimiliano ;
Pruneri, Giancarlo ;
Serrano, Davide ;
Guerrieri-Gonzaga, Aliana ;
Gennari, Alessandra ;
Trabacca, Maria Stella ;
Galimberti, Viviana ;
Veronesi, Paolo ;
Johansson, Harriet ;
Aristarco, Valentina ;
Bassi, Fabio ;
Luini, Alberto ;
Lazzeroni, Matteo ;
Varricchio, Clara ;
Viale, Giuseppe ;
Bruzzi, Paolo ;
DeCensi, Andrea .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2593-2600
[7]   Use of statins and breast cancer: A meta-analysis of seven randomized clinical trials and nine observational studies [J].
Bonovas, S ;
Filioussi, K ;
Tsavaris, N ;
Sitaras, NM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8606-8612
[8]   Breast cancer chemoprevention: little progress in practice? [J].
Cameron, David A. .
LANCET, 2014, 383 (9922) :1018-1020
[9]   Exposure to oral bisphosphonates and risk of cancer [J].
Cardwell, Chris R. ;
Abnet, Christian C. ;
Veal, Philip ;
Hughes, Carmel M. ;
Cantwell, Marie M. ;
Murray, Liam J. .
INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (05) :E717-E725
[10]   Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial [J].
Cauley, JA ;
Norton, L ;
Lippman, ME ;
Eckert, S ;
Krueger, KA ;
Purdie, DW ;
Farrerons, J ;
Karasik, A ;
Mellstrom, D ;
Ng, KW ;
Stepan, JJ ;
Powles, TJ ;
Morrow, M ;
Costa, A ;
Silfen, SL ;
Walls, EL ;
Schmitt, H ;
Muchmore, DB ;
Jordan, VC .
BREAST CANCER RESEARCH AND TREATMENT, 2001, 65 (02) :125-134
1234567